Skip to main content

Table 3 Baseline characteristics of patients given definitive monotherapy with a BLBLI or carbapenem

From: Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae

Patient characteristic

Definitive treatment cohort

Total study population

BLBLI (N = 24)

Carbapenem (N = 23)

N = 91

Age, median [IQR], years

77 [61–83]

77 [68–83]

75 [62–83]

Female

13 (54%)

12 (52%)

49 (54%)

Hospital acquired

7 (29%)

4 (17%)

20 (22%)

Community acquired

7 (29%)

9 (39%)

42 (46%)

Healthcare associated

10 (42%)

10 (43%)

29 (32%)

CCI, median [IQR]

2 [1-4]

2 [1-5]

2 [1-4]

Pitt score, median [IQR]

1 [0–2]

1 [0–3]

1 [0–2]

APACHEII (if ICU), median [IQR]

26

20

24 [15-28]

ICU admission

2 (8%)

5 (22%)

11 (12.1)

E. coli

22 (92%)

17 (74%)

79 (87%)

Source:

   

Hepato-biliary

2 (8%)

2 (9%)

12 (13%)

Urinary tract

9 (38%)

13 (57%)

43 (47%)

Neutropenic sepsis

1 (4%)

0 (0%)

4 (4%)

Other/unknown source

12 (50%)

8 (34%)

32 (35%)

Co-morbidity/devices:

   

Moderate to severe liver disease

3 (13%)

1 (4%)

7 (8%)

Diabetes without end organ damage

6 (25%)

5 (22%)

21 (23%)

Diabetes with organ damage

4 (17%)

5 (22%)

15 (17%)

Moderate to severe renal disease

4 (17%)

7 (31%)

19 (21%)

Metastatic solid tumour

1 (4%)

1 (4%)

4 (4%)

Leukaemia or lymphoma

1 (4%)

2 (9%)

7 (8%)

Urinary device

5 (21%)

3 (13%)

15 (17%)

Immunosuppressive treatments

2 (8%)

4 (17%)

12 (13%)

Empirical therapy:

   

3GC

7 (29%)

6 (26%)

33 (36%)

BLBLI

11 (46%)

5 (22%)

25 (28%)

Carbapenem

0 (0%)

2 (9%)

8 (9%)

Other*

6 (25%)

10 (43%)

25 (27%)

Appropriate empirical therapy

15 (63%)

15 (65%)

50 (55%)

  1. *Including combinations of carbapenem/BLBLI/3CG.
  2. CCI = Charlson Co-morbidity index, IQR = Inter-quartile range, ICU = intensive care unit, 3GC = third-generation cephalosporins, BLBLI = beta-lactam/beta-lactamase inhibitor.